Patents Assigned to Intarcia Therapeutics, Inc.
-
Patent number: 11739134Abstract: This invention relates to isolated polypeptides that are long acting analogs of human PYY. The disclosed PYY analog polypeptides have beneficial physicochemical properties relative to endogenous PYY and known synthetic PYY analog polypeptides, such as longer (i.e., “long-acting”) elimination half-lives (t1/2), and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed PYY analog polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed PYY analog polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as type 2 diabetes, treating obesity, and providing weight loss, and in methods of treating nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH).Type: GrantFiled: April 16, 2021Date of Patent: August 29, 2023Assignee: Intarcia Therapeutics, Inc.Inventors: William Blackwell, Ved P. Srivastava, James M. Way
-
Patent number: 11654183Abstract: Provided is a method for administering to a subject, via an implantable delivery device, a continuous subcutaneous dose of glucagon-like peptide-1 (GLP-1) analog, where the subject is orally co-administered a drug after implantation of the implantable delivery device and during continuous subcutaneous dosing of the GLP-1 analog.Type: GrantFiled: October 13, 2020Date of Patent: May 23, 2023Assignee: INTARCIA THERAPEUTICS, INC.Inventors: Andrew Young, Michelle Baron
-
Patent number: 11246913Abstract: A suspension formulation of an insulinotropic peptide (e.g., glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic peptide, wherein the peptide is dispersed in the vehicle. The particle formulation further includes a stabilizing component comprising one or more stabilizers, for example, carbohydrates, antioxidants, amino acids, and buffers. Devices for delivering the suspension formulations and methods of use are also described.Type: GrantFiled: June 14, 2019Date of Patent: February 15, 2022Assignee: Intarcia Therapeutics, Inc.Inventors: Thomas R. Alessi, Ryan D. Mercer, Catherine M. Rohloff, Bing Yang
-
Patent number: 11214607Abstract: This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.Type: GrantFiled: October 29, 2019Date of Patent: January 4, 2022Assignee: Intarcia Therapeutics Inc.Inventors: William Blackwell, Ved P. Srivastava, Mark A. Paulik, Andrew Young, Robert Neil Hunter, III, Steven Thomas Dock
-
Patent number: 10925639Abstract: Devices, methods, and systems are provided for placing an implant into a patient and removing it therefrom.Type: GrantFiled: June 2, 2016Date of Patent: February 23, 2021Assignee: Intarcia Therapeutics, Inc.Inventors: Jay S. Smith, Michael R. Cole, James M. Sellers, Scott D. Lautenbach, Amy K. Whitson, Matthew Weber
-
Patent number: 10869830Abstract: The present invention is directed to treatment methods for a disease or condition, in a subject in need of such treatment, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery. The method typically includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is typically achieved within about 7 days or less after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2 diabetes mellitus using incretin mimetics.Type: GrantFiled: July 6, 2018Date of Patent: December 22, 2020Assignee: INTARCIA THERAPEUTICS, INC.Inventors: Thomas R. Alessi, Kenneth Luskey
-
Patent number: 10835580Abstract: Provided is a method for administering to a subject, via an implantable delivery device, a continuous subcutaneous dose of glucagon-like peptide-1 (GLP-1) analog, where the subject is orally co-administered a drug after implantation of the implantable delivery device and during continuous subcutaneous dosing of the GLP-1 analog.Type: GrantFiled: January 3, 2018Date of Patent: November 17, 2020Assignee: INTARCIA THERAPEUTICS, INC.Inventors: Andrew Young, Michelle Baron
-
Patent number: 10583080Abstract: The present invention is directed to treatments for a disease or condition, in a subject in need thereof, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery. The method includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is achieved within about 7 days after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2 diabetes mellitus using insulinotrophic peptides. In embodiments, a subject has a baseline HbA1c % of greater than 6.5% or 10.0%.Type: GrantFiled: January 11, 2018Date of Patent: March 10, 2020Assignee: INTARCIA THERAPEUTICS, INC.Inventors: Thomas R. Alessi, Michelle Baron
-
Patent number: 10527170Abstract: An osmotic delivery system is disclosed for delivering an active agent formulation to a fluid environment. The osmotic delivery system typically comprises a reservoir having a lumen that contains the active agent formulation and an osmotic agent formulation and a piston assembly positioned in the lumen to isolate the active agent formulation from the osmotic agent formulation. The piston assembly typically comprises a body constructed and arranged for positioning in the lumen. The body is typically made of a polymeric material that is, for example, resistant to leaching in an organic solvent. In one embodiment, the body is a columnar body having a rim at a distal end thereof for engaging and sealing against a wall of the reservoir and the piston assembly further comprises a spring retained at the distal end of the columnar body for biasing the rim of the columnar body against the wall of the reservoir.Type: GrantFiled: June 27, 2014Date of Patent: January 7, 2020Assignee: INTARCIA THERAPEUTICS, INC.Inventors: Thomas R. Alessi, Michael A. DesJardin, Stan Lam, Scott D. Lautenbach, Pauline C. Zamora
-
Patent number: 10501517Abstract: This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.Type: GrantFiled: May 15, 2017Date of Patent: December 10, 2019Assignee: INTARCIA THERAPEUTICS, INC.Inventors: William Blackwell, Ved P. Srivastava, Mark A. Paulik, Andrew Young, Robert Neil Hunter, III, Steven Thomas Dock
-
Patent number: 10441528Abstract: The present invention relates to osmotic delivery devices, formulations, and methods for delivery of two or more beneficial agents. In one aspect, the present invention provides osmotic delivery devices useful for substantially concurrent administration of two or more beneficial agents. In another aspect, the present invention provides beneficial agent formulations for use in the osmotic delivery devices. The formulations include formulations wherein beneficial agents are soluble in the vehicle, suspension formulations comprising particle formulations of one or more beneficial agent, and combinations thereof. Further, methods for treatment of a variety of diseases or conditions using two or more beneficial agents are disclosed, wherein the methods are preferably practiced using the osmotic delivery devices and/or formulations of the invention.Type: GrantFiled: March 16, 2018Date of Patent: October 15, 2019Assignee: INTARCIA THERAPEUTICS, INC.Inventors: Thomas R. Alessi, Karling Alice Leung, Ryan D. Mercer, Cristina G. Negulescu, Catherine Manya Rohloff, Bing Yang
-
Patent number: 10363287Abstract: A suspension formulation of an insulinotropic peptide (e.g., glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic peptide, wherein the peptide is dispersed in the vehicle. The particle formulation further includes a stabilizing component comprising one or more stabilizers, for example, carbohydrates, antioxidants, amino acids, and buffers. Devices for delivering the suspension formulations and methods of use are also described.Type: GrantFiled: June 2, 2017Date of Patent: July 30, 2019Assignee: INTARCIA THERAPEUTICS, INC.Inventors: Thomas R. Alessi, Ryan D. Mercer, Catherine M. Rohloff, Bing Yang
-
Patent number: 10231923Abstract: The present invention is directed to treatment methods for a disease or condition, in a subject in need of such treatment, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery. The method typically includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is typically achieved within about 7 days or less after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2 diabetes mellitus using incretin mimetics.Type: GrantFiled: August 22, 2016Date of Patent: March 19, 2019Assignee: INTARCIA THERAPEUTICS, INC.Inventors: Thomas R. Alessi, Kenneth Luskey
-
Patent number: 10159714Abstract: The use of GLP-1 receptor agonists, such as glucagon-like peptide-1 (GLP-1) or exenatide, for the treatment of cancer is described. The GLP-1 receptor agonists are typically delivered using an implanted osmotic delivery device that provides for continuous delivery of the GLP-1 receptor agonist for at least one month. Additional beneficial agents, such as anticancer agents, can also be administered.Type: GrantFiled: May 17, 2017Date of Patent: December 25, 2018Assignee: Intarcia Therapeutics, Inc.Inventor: Karling Alice Leung
-
Patent number: D835783Type: GrantFiled: May 19, 2017Date of Patent: December 11, 2018Assignee: Intarcia Therapeutics, Inc.Inventors: Jay S. Smith, Michael R. Cole, Amy K. Whitson
-
Patent number: D840030Type: GrantFiled: June 2, 2016Date of Patent: February 5, 2019Assignee: Intarcia Therapeutics, Inc.Inventors: Jay S. Smith, Michael R. Cole, Amy K. Whitson
-
Patent number: D860451Type: GrantFiled: June 2, 2016Date of Patent: September 17, 2019Assignee: Intarcia Therapeutics, Inc.Inventors: Jay S. Smith, Michael R. Cole
-
Patent number: D912249Type: GrantFiled: July 24, 2019Date of Patent: March 2, 2021Assignee: INTARCIA THERAPEUTICS, INC.Inventors: Jay S. Smith, Michael R. Cole
-
Patent number: D933219Type: GrantFiled: July 13, 2018Date of Patent: October 12, 2021Assignee: INTARCIA THERAPEUTICS, INC.Inventors: Jay S. Smith, Matthew Weber, James M. Sellers, Michael R. Cole, Amy K. Whitson, Rehan Azeem
-
Patent number: D962433Type: GrantFiled: October 23, 2018Date of Patent: August 30, 2022Assignee: Intarcia Therapeutics, Inc.Inventors: Jay S. Smith, Michael R. Cole, Amy K. Whitson